Abstract
An intracellular hallmark of Alzheimer’s Disease (AD) is accumulation of hyperphosphorylated tau as paired helical filaments (PHF). A significant advance in understanding the behavior of tau occurred when it was reported that VQIVYK hexapeptide motif is responsible for initiating the process of aggregation. In the last years, a great number of Tau aggregation inhibitors have been developed, including flavonoids. However, the binding mode of these potential drugs is not well established. In this work, the behavior and conformational stability of the Tau hexapeptide306VQIVYK311 were investigated in the presence of two known flavonoid inhibitors using Molecular Interaction Fields (MIFs), pharmacophore perception and molecular dynamics (MD) simulations. We have also proposed a likely binding mode for such inhibitors with the hexapeptide, which agrees with experimental data and is able to explain structure-activity relationships between different flavonoids.
Keywords: Alzheimer’s disease, tau protein, flavonoids, molecular interaction fields, pharmacophore perception, molecular dynamics simulations
Current Bioactive Compounds
Title:In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease
Volume: 9 Issue: 1
Author(s): Susimaire Pedersoli-Mantoani, Carlos Henrique Tomich de Paula da Silva and Vinicius Barreto da Silva
Affiliation:
Keywords: Alzheimer’s disease, tau protein, flavonoids, molecular interaction fields, pharmacophore perception, molecular dynamics simulations
Abstract: An intracellular hallmark of Alzheimer’s Disease (AD) is accumulation of hyperphosphorylated tau as paired helical filaments (PHF). A significant advance in understanding the behavior of tau occurred when it was reported that VQIVYK hexapeptide motif is responsible for initiating the process of aggregation. In the last years, a great number of Tau aggregation inhibitors have been developed, including flavonoids. However, the binding mode of these potential drugs is not well established. In this work, the behavior and conformational stability of the Tau hexapeptide306VQIVYK311 were investigated in the presence of two known flavonoid inhibitors using Molecular Interaction Fields (MIFs), pharmacophore perception and molecular dynamics (MD) simulations. We have also proposed a likely binding mode for such inhibitors with the hexapeptide, which agrees with experimental data and is able to explain structure-activity relationships between different flavonoids.
Export Options
About this article
Cite this article as:
Pedersoli-Mantoani Susimaire, Henrique Tomich de Paula da Silva Carlos and Barreto da Silva Vinicius, In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease, Current Bioactive Compounds 2013; 9 (1) . https://dx.doi.org/10.2174/1573407211309010004
DOI https://dx.doi.org/10.2174/1573407211309010004 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Virgin Olive Oil and Hypertension
Current Vascular Pharmacology Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology The CD4C/HIVNef Transgenic Model of AIDS
Current HIV Research Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Anti-Aggregating Antibodies, a New Approach Towards Treatment of Conformational Diseases
Current Medicinal Chemistry Exploring Natural Products as a Source for Antidiabetic Lead Compounds and Possible Lead Optimization
Current Topics in Medicinal Chemistry Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Optimizing Modifiable and Lifestyle-related Factors in the Prevention of Dementia Disorders with Special Reference to Alzheimer, Parkinson and Autism Diseases
Current Nutrition & Food Science Influence of Hypertension, Alone and in Combination with Other Vascular Risk Factors on Cognition
CNS & Neurological Disorders - Drug Targets PUFA Supplements and Type 2 Diabetes in the Elderly
Current Pharmaceutical Design Editorial: Impact of Racial Differences on Brain Health among the Oldest Old
Current Alzheimer Research Apolipoprotein E Gene Revisited: Contribution of Rare Variants to Alzheimer’s Disease Susceptibility in Southern Chinese
Current Alzheimer Research Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug
Current Topics in Medicinal Chemistry Does an Interdisciplinary Network Improve Dementia Care? Results from the IDemUck-Study
Current Alzheimer Research Is Age of 80 Years a Threshold for Carotid Revascularization?
Current Cardiology Reviews The New Challenges of Brain PET Imaging Technology
Current Medical Imaging